Key Facts
• July 2025: U.S. drug price reduction policy remains unclear after one month.
• Trump administration proposed pricing based on most-favored-nation status.
• U.S. drug prices are 63% higher than Japan’s for patented medicines.
• U.S. pricing allows negotiation between insurers and pharmaceutical firms.
• Japan’s drug prices decrease post-launch due to price revisions.
• Merck Japan’s president predicts potential global development delays.
• U.S. price cuts may influence Japan and Europe to lower their drug prices.
• Japan’s pharmaceutical market is stable with high medical access and prescription levels.
• Takeda Pharmaceuticals advocates for reform to attract global drug development.
• Japan Pharmaceutical Manufacturers Association emphasizes value-based pricing.
Summary
The U.S. drug price reduction policy, initiated by the Trump administration, has left pharmaceutical companies uncertain about its impact. The policy aims to align U.S. drug prices with those of other nations, where prices are significantly lower. Japan’s drug prices, for instance, are 63% lower than the U.S. for patented medicines. While U.S. pricing reflects development costs through insurer negotiations, Japan’s system focuses on post-launch price reductions, creating disparities. Industry leaders, including Merck Japan, warn of potential global development delays if U.S. prices drop, as other regions may follow suit. Despite concerns, Japan’s stable market, characterized by high medical access and prescription levels, presents opportunities for attracting global pharmaceutical development. Takeda Pharmaceuticals and the Japan Pharmaceutical Manufacturers Association advocate for reforms to ensure value-based pricing and maintain Japan’s market appeal.
